VUS, CHEK2-related management in prostate cancer to be discussed in virtual genetics board

Author(s):

“We’re going to review CHEK2-related management guidelines, hereditary cancer implications for males and their families…and the importance of cascade testing,” says Veda N. Giri, MD.

In this video, Veda N. Giri, MD, previews the upcoming ENGAGEMENT study virtual genetics board’s February case discussion (https://www.prostategenetics.com/engagement). Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.